A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan. - Full Text View

Sponsored by:	Novartis
Information provided by:	Novartis
ClinicalTrials.gov Identifier:	NCT00250562

Purpose

Valsartan, an orally active angiotensin II receptor blocker, is registered in most countries worldwide for the treatment of hypertension. In China the usual recommended starting and maintenance dose is 80 mg o.d. The combination of HCTZ 12.5 mg with valsartan 80 mg has been shown to have additive effects in lowering blood pressure compared to valsartan 80 mg in patients not adequately controlled by valsartan 80 mg monotherapy5 or in non-selected patients6. This fixed combination is registered in most countries worldwide.

The potential benefits of these combinations should be evaluated in patients not adequately controlled by valsartan 80 mg monotherapy. This study will compare the efficacy, safety and tolerability of adding HCTZ 12.5 mg to valsartan 80 mg in those hypertensive patients.

This study is not recruiting in the US.

Condition	Intervention	Phase
Hypertension	Drug: valsartan plus hydrochlorothiazide	Phase III

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Valsartan Hydrochlorothiazide Angiotensin II Angiotensin II, ile(5)-

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Multicenter, Double-Blind, Randomized, Active Controlled, Parallel Group Trial Comparing the Combinations of Valsartan 80 Mg Plus Hydrochlorothiazide 12.5 Mg to Valsartan 80 Mg in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Valsartan 80mg

Further study details as provided by Novartis:

Primary Outcome Measures:

Change from baseline diastolic blood pressure after 8 weeks

Secondary Outcome Measures:

Change from baseline systolic blood pressure after 8 weeks
Diastolic blood pressure less than 90 mmHg or at least a 10 mmHg decrease in diastolic blood pressure after 8 weeks

Estimated Enrollment:

752

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

- Male or female Outpatients 18 years and older.
Patients with hypertension defined as the following:
Newly diagnosed hypertensive patients should have a MSDBP > 95 mmHg and < 110 mmHg.at Visit 1 and 2, Pre-treated hypertensive patients should have a MSDBP > 95 mmHg and < 110 mmHg at Visit 2
For entrance into the double-blind treatment period (Visit 3), all patients should have a MSDBP of > 90 mmHg and < 110 mmHg
Patients must have given written informed consent to participate and be willing to participate in the entire study

Exclusion Criteria:

-

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00250562

Locations

United States, New Jersey
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936

Sponsors and Collaborators

Novartis

Investigators

Study Director:

Novartis Pharmaceutical

Novartis Pharmaceuticals

More Information

Study ID Numbers:	CVAH631A2302
Study First Received:	November 6, 2005
Last Updated:	June 1, 2006
ClinicalTrials.gov Identifier:	NCT00250562
Health Authority:	China: Ministry of Health

Keywords provided by Novartis:

Hypertension
Angiotensin II receptor blocker
fixed combination
diuretics

Study placed in the following topic categories:

Vascular Diseases
Essential hypertension
Angiotensin II

Hydrochlorothiazide
Valsartan
Hypertension

Additional relevant MeSH terms:

Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Therapeutic Uses
Sodium Chloride Symporter Inhibitors
Physiological Effects of Drugs

Diuretics
Cardiovascular Diseases
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009